Abstract
Self-assembled polymersomes encapsulate, protect, and deliver hydrophobic and hydrophilic drugs. Though spherical polymersomes are effective, early studies suggest that non-spherical structures may enhance specificity of delivery and uptake due to similarity to endogenous uptake targets. Here we describe a method to obtain persistent non-spherical shapes, prolates, via osmotic pressure and the effect of prolates on uptake behavior. Polyethylene glycol-b-poly(lactic acid) polymersomes change in diameter from 145 ± 6 nm to 191 ± 1 nm and increase in polydispersity from 0.05 ± 0.02 to 0.12 ± 0.01 nm after addition of 50 mM salt. Transmission and scanning electron microscopy confirm changes from spheres to prolates. Prolate-like polymersomes maintain their shape in 50 mM NaCl for seven days. Nile Red and bovine serum albumin-Fluorescein dyes are taken up in greater amounts by SH-SY5Y neural cells when encapsulated in polymersomes. Prolate polymersomes may be taken up more efficiently in neural cells than spherical polymersomes.
Keywords: polymersomes, shape effects, brain delivery, nanoparticles, shape modulation, self-assembly
Introduction
Polymeric nanoparticles, namely polymersomes, have gained traction as a potential solution to drug targeting and delivery due to their ability to encapsulate both hydrophilic and hydrophobic molecules, offer immune shielding, and exhibit low toxicity. Polymersomes are bilayer, membrane-bound vesicles comprised of hydrophilic and hydrophobic polymers, with a ratio of approximately 25%–40% by weight hydrophilic [1]. Based on the polymers selected, polymersomes can release due to pathophysiologic changes in the diseased area. For example, polymersomes can respond to pH [2–9], hypoxia [10–12], and temperature [13]. Therefore, manipulation of these properties is considered a viable tool in creating drug delivery systems.
The physical properties of these nanoparticles, in our case highly monodisperse polyethylene glycol-b-poly (lactic acid) (PEGPLA) polymersomes, have been implicated as important factors in the physical mechanisms of uptake. Properties such as size, shape, charge, and material are all being studied in order to determine how to best assign these nano-vesicles with a desired uptake pathway. Natural uptake targets, such as proteins, are usually not perfectly spherical but rather exhibit a variety of morphologies. Mimicking these morphologies could allow for higher, more specific delivery that imparts less stress upon the body. For example, targeted, rod-like polystyrene nanoparticles accumulated in Caco-2 and Caco-2/HT-29 cells to a greater extent than spherical and disc like particles [14]. Similarly, long rods of mesoporous silica covered in PEG demonstrated approximately five-fold greater uptake in HeLa cells compared to short rods and spherical PEGylated particles [15]. The ability of HeLa cells to better internalize rod-like particles has been previously studied and reviewed [16]. Specifically, prolate shaped nanoparticles exhibit higher aspect ratios, providing greater surface area for uptake via invagination. The idea of utilizing different nanoparticle shapes for enhanced biologic uptake in a diseased area is not a new one. Kolhar et al found that polystyrene nanorods showed higher targeted uptake towards the endothelium compared with spherical particles, confirmed by both in vitro and in vivo assays. Furthermore, the greatest discrepancy in uptake was observed in the brains of mice, where drugs typically exhibit low efficiency [17–27], where targeted polystyrene rods were taken up in 7.5× greater amounts than targeted polystyrene spheres [28]. We extended this application to self-assembled systems, capable of delivering more than one drug simultaneously.
Disease treatment often requires a combination, or cocktail, of drugs working synergistically in order to achieve desired outcomes. Due to the complex biochemical pathology of most diseases, treatments benefit from the ability to administer multiple therapeutics simultaneously. Specifically, cells are more naturally susceptible to hydrophobic molecules. Many peptide-based therapies, plant-based anti-inflammatories, and antibiotics are unable to diffuse across cellular membranes, rendering them ineffective for treatment of many diseases, including brain disease. The creation of drug delivery systems, such as the one proposed in this paper, which allow the simultaneous delivery of drugs or therapeutic molecules with a range of hydrophobicity and hydrophilicity, show promise in tackling a variety of complex biological problems.
Polymersomes have been transformed to achieve a variety of shapes including rods and stomatocytes [29, 30]. More complex structures, such as nested vesicles, have also been achieved [31, 32]. The primary method of achieving these transformations is osmotic shock, creating an osmotic pressure gradient causing the movement of water molecules either into or out of self-assembled structures. Osmotic shock has resulted in shape changes through the addition of NaCl [33], glucose [31], or PEG [32]. Herein we report that PEGPLA polymersomes are capable of encapsulating hydrophilic and hydrophobic compounds simultaneously, and that loaded polymersomes deliver encapsulated compounds to cells more effectively than free dye alone. We confirm that subjecting PEGPLA polymersomes to 50 mM NaCl solution via dialysis, as reported by Wauters et al, results in a change in shape from spheres to prolates [33]. Furthermore, we report that this shape change is complimented by an increase in the amount of both hydrophobic and hydrophilic compounds retained in the polymersomes.
We employed simple, yet effective methods of achieving persistent shape change in polymersomes and investigated how these changes influence the ability of the polymersomes to co-deliver drug payloads. Through the manipulation of the ionic gradient in the suspension of polymersomes, achieved via dialysis in NaCl, we show polymersomes in prolate form persist over time. Furthermore, these prolate nanoparticles were more effectively taken up by human neural cells (SH-SY5Y) in vitro. In this paper, we explore the safety and efficacy of prolate polymersomes as a potential delivery system, vetting their potential to enhance uptake behavior into brain cells. The combination of morphologically tuned prolate particles with amphiphilic encapsulation promise potential in providing minimally invasive procedures for currently untreatable diseases.
Results and discussion
The general concept for modulating spherical polymersomes to prolates by exposure to hypertonic conditions is introduced in figure 1. Polymersomes are formed by a process of self-assembly in an aqueous solution wherein the hydrophobic portions of the diblock copolymers align to form a bilayer membrane [1]. PEG1000Da-b-PLA5000Da (PEGPLA) forms highly, stable spherical polymersomes via solvent injection, as described in the methods section, with properties listed in the first row of table 1. In water, consistent sizes were observed, demonstrated by a small standard deviation in diameter and low polydispersities. Upon removal of organic solvent from the suspension of polymersomes, the polymersomes appear to approach a critical size (figure 2) around 190 nm. In vitro blood-brain barrier studies indicate that nanoparticles of 200 nm or less are preferentially transported through to the abluminal side [34–36], making our nanoparticles capable of similar transport behavior.
Figure 1.

Polymersome shape change. Osmosis across polymersome membrane due to hypertonic conditions, resulting in a prolate shape.
Table 1.
Characterization by dynamic light scattering of PEGPLA polymersomes without NaCl and with NaCl at 50 mM.
| Material | NaCl | Diameter ± SD (nm) | Zeta potential ± SD (mV) | PDI ± SD |
|---|---|---|---|---|
|
| ||||
| PEGPLA | − | 145.5 ± 6.1 | −41.6 ± 1.7 | 0.05 ± 0.02 |
| + | 190.9 ± 1.3 | −19.3 ± 1.6 | 0.12 ± 0.01 | |
Figure 2.

Dialysis of spherical polymersomes. Each sample was made from PEGPLA block co-polymer dissolved in DMSO at an equal concentration of 3 mM. The 20%, 10%, and 5% samples contained 3.6 mg, 1.8 mg, and 0.9 mg of PEGPLA dissolved in 200 μl, 100 μl and 50 μl DMSO, respectively. The samples were injected into DI water such that the final volume for each sample was 1 ml. Polymersome samples were then dialyzed against DI water at dialysate volumes such that the final DMSO concentration in each sample was the same, resulting in similar final diameters.
Not unlike biological bilayer membranes, self-assembled PEGPLA polymersomes are affected by osmosis. Exposure of polymersomes to hypertonic conditions by dialysis against a salt (NaCl) solution provokes the outward diffusion of water from the core of the polymersomes [30]. In contrast to phospholipids, which make up cell membranes, the hydrophobic portion of diblock copolymers in the membrane of polymersomes are much longer, theoretically inhibiting the passage of sodium or chloride ions through the membrane to the aqueous core. The resulting effect is a decreased inner volume of polymersomes. Spherical polymersomes were dialyzed against 50 mM NaCl to create hypertonic conditions, causing a shift in thermodynamic equilibrium, resulting in a shape change. In the presence of salt, sizes became less consistent, with an increase in diameter size and polydispersity (second row, table 1). Because dynamic light scattering assumes spherical shape [37], an increase in perceived polydispersity could be due to an increase in aspect ratio, leading to measurements with a wider range of sizes based on the orientation of the particle in solution when the laser contacts it. Zeta potential measurements indicate that both prolates and spherical polymersomes are stable in solution, with values around or less than −20 mV [38].
When the inner volume decreases and the surface area of the polymersomes remains constant, a shape change is observed (figures 3, 4). Without NaCl, PEGPLA polymersomes present as spherical structures with a brush-like exterior layer, observable through the rough surface presentation in SEM. After the addition of NaCl, PEGPLA polymersomes lose their spherical morphology and appear more worm-like, indicative of a shift in shape (figure 3). TEM images lead to the same conclusions, showing much longer and oval-like structures after the addition of NaCl. Without NaCl, PEGPLA polymersomes appear as membrane-bound spherical structures with a relatively monodisperse distribution, confirmed through dynamic light scattering (table 1). With the addition of 50 mM NaCl, PEGPLA polymersomes become prolate structures with an aspect ratio around two, with the longest radius being approximately twice the size of the shortest radius (figure 4). For the purpose of drug delivery applications, it is important that membrane-bound prolates, or prolate polymersomes, maintain their shape over an extended period. Prolates maintain their structure over a period of one week in isotonic solution, as shown by minimal changes in both z-average diameter and polydispersity indices (figure 5). Prolate polymersomes appear to have a three-day settling period, where diffusion of solvent out of the hydrophobic membrane is believed to be occurring and diameter and polydispersity index are slowly decreasing. However, after seeing a statistically significant (p < 0.05) decrease in both size and polydispersity index from days 3 to 4, prolate polymersomes stabilize and maintain their sizes over the remaining days. It is important to note that these sizes and PDIs are still significantly larger than spherical polymersomes made without the presence of NaCl.
Figure 3.

Scanning electron microscopy images of spherical and prolate nanoparticles. Without salt dialysis (L), SEM images display self-assembled spheres with a fuzzy brush, indicative of a fully extended PEG layer. Post salt dialysis (R), SEM images display more oblong, rod-like structures (LHS Scale Bar: 500 nm; RHS Scale Bar: 1.00 μm).
Figure 4.

Transmission electron microscopy images of spherical and prolate nanoparticles. Spherical and prolate particles were dried from a 0 mM and 50 mM NaCl suspension, respectively and stained with uranyl acetate. Without NaCl, PEGPLA polymersomes appear as membrane bound spherical structures with a monodisperse distribution (L). With NaCl, PEGPLA are prolate structures with an aspect ratio around 2, with the longest radius being two times the size of the shortest radius (R). Images taken at 120 kV/60 000× direct mag on Hitachi h7600 transmission electron microscope. (LHS Scale Bar: 2.0 μm, RHS Scale Bar: 500 nm)
Figure 5.

Persistent prolate shape. DLS measurements of Z-Avg (d. nm) and PDI for prolate polymersomes persisting over 7 d.
Interestingly, this loss of inner volume does not result in a lower degree of encapsulation for hydrophilic or hydrophobic molecules, but rather a higher degree of retainment. Nile Red and bovine serum albumin (BSA)-Fluorescein were used as model hydrophobic and hydrophilic drugs, respectively. In general, Nile red is encapsulated at a lower efficiency than BSA-Fluorescein due to the smaller hydrophobic volume available in the membrane in comparison to the hydrophilic core. It is assumed that prior to dialysis and shape change, all samples contain the same internal concentration of encapsulated molecules; therefore, the final internal concentration for both molecules must be a result of the polymersomes’ ability to retain the molecules (table 2). Therefore, we believe the loss of inner volume is not what is responsible for the higher concentration of BSA-Fluorescein and Nile Red in prolate samples, but rather that the NaCl plays some role in the retaining of encapsulated molecules, based on studies of BSA encapsulation in microspheres [39] and studies that show salts are capable of complexing with payloads to prevent leakage in liposomes [40]. However, this was not investigated further in our system, but might be an interesting subject for future studies. Although loading efficiency is different in spheres versus prolates, release behavior in pH 4.8 appears to be the same over a period of 48 h after being normalized to encapsulation efficiency, which is expected because both nanoparticle shapes are created from the same material (figure 6). A pH of 4.8 was chosen due to the pH change that occurs in an early endo-lysosome, which is the most likely route of internalization of these untargeted particles.
Table 2.
Polymersomes encapsulation of multiple compounds. Retainment of encapsulated dye (Nile Red and Albumin-Fluorescein) by PEGPLA nanoparticles following dialysis against MilliQ water and NaCl for spheres and prolates, respectively.
| Nile Red |
BSA-Fluorescein |
|||||
|---|---|---|---|---|---|---|
| Material | NaCl | Shape | EF ± SD (%) | Loading content (μg dye/mg polymer) | EF ± SD (%) | Loading content (μg dye/mg polymer) |
|
| ||||||
| PEGPLA | − | Sphere | 5.2 ± 0.4 | 1.7 ± 0.0 | 13.9 ± 1.2 | 46.5 ± 4.0 |
| + | Prolate | 10.9 ± 0.3 | 3.6 ± 0.1 | 23.06 ± 9.4 | 78.5 ± 31.4 | |
Figure 6.

Release of FITC-Dextran from polymersomes. In pH 4.8 Citrate buffer, both spheres and prolates demonstrate statistically identical release behavior.
Prolate shaped particles appear to deliver both BSA-Fluorescein and Nile Red more effectively to SH-SY5Y neuroblastoma cells based on fluorescent images (figure 7). Intensity of both Nile Red and BSA-Fluorescein is greater when prolate polymersomes were incubated with SH-SY5Y cells. This may be due in part to the higher retainment of both compounds (table 2). However, this may result from a tendency for cells to take up non-spherical nanoparticles more effectively than spherical nanoparticles, an attribute of the flattened prolate shape granting a greater surface area to contact the cellular surface. Analysis of SH-SY5Y uptake of BSA-Fluorescein by flow cytometry (figure 8) shows significantly more dye was taken up by SH-SY5Y cells when encapsulated in polymersomes compared to free dye, regardless of shape. The difference in dye uptake between polymersome shapes is trending toward significance, with SH-SY5Y cells appearing to have slightly more internal fluorescence when treated with prolate polymersomes. To make these results more conclusive, more cells could be seeded for analysis as SH-SY5Y cells are partially adherent. SH-SY5Y cells are frequently differentiated into neurons for uptake studies [41–44], which may also increase adherence. Uptake differences may be due to the change in aspect ratio from spheres to prolates not being large enough to have a significant effect on cell uptake. As demonstrated by Huang et al, the larger the aspect ratio, the greater than internalization rate with regards to silica-based systems [45]. To confirm this hypothesis, further work needs to be performed on various self-assembled aspect ratios.
Figure 7.

Cell uptake of polymersomes containing multiple compounds. Fluorescent images of SH-SY5Y uptake of BSA-Fluorescein (green) and Nile Red (red) after incubation with either spherical or prolate polymersomes for four hours. Nucleus stained with DAPI (blue).
Figure 8.

Cell uptake of polymersomes containing multiple compounds confirmed with flow cytometry. After 72 h, SH-SY5Y cells were analyzed in flow cytometry. Both spherical and prolate polymersomes lead to greater uptake than free dye (p < 0.05). Prolates are trending towards increased uptake compared to spherical polymersomes.
In summary, PEGPLA polymersomes are able to be shifted from a spherical to a more prolate-like shape. To our knowledge, this is the first time self-assembled prolates have been compared to self-assembled spheres with regards to simultaneous hydrophobic and hydrophilic drug delivery. Prolates are capable of encapsulating more of both BSA-fluorescein and Nile Red than their spherical counterparts, which could contribute to the increased intracellular fluorescence observed when cultured with SH-SY5Y neuroblastoma cells. Increasing aspect ratios may be able to increase uptake efficiencies, based on the only slight difference in uptake seen in flow cytometry. Through modulating nanoparticle shape, we are able to enhance uptake of both hydrophilic and hydrophobic drugs into neural cells, which provides promising results towards enhancing uptake in other cell lines, with the ultimate goal of efficiently delivering payloads through the blood-brain barrier.
Methods
Polymersome preparation
Monodisperse spherical polymersomes of polyethylene glycol (PEG)1000Da-b-polylactic acid (PLA)5000Da (Polyscience, Inc.) were obtained by dissolving the polymer in dimethyl sulfoxide (DMSO) at 15 mg ml−1 then infusing 100 μl of the polymer solution into 1 ml of MilliQ water at 5 μl min−1 and stirring at 100 rpm using a Legato Syringe Pump. For spherical samples, polymersomes were dialyzed in 300 kDa membrane from Spectrum Laboratories against MilliQ water for 15 h to remove DMSO. Polymersome size and polydispersity were characterized by dynamic light scattering using Malvern Zetasizer Nano ZS.
Shape modulation
Upon assembly, polymersomes are spherical and in isotonic conditions. To achieve prolate morphology, samples were subjected to hypertonic conditions. Following infusion, samples, samples were dialyzed against 50 mM NaCl solution for 15 h. To minimize interference, all TEM and SEM imaging was done after an additional dialysis of prolate samples against MilliQ water to remove the salt. TEM and SEM imaging was done with HT7830 transmission electron microscope and high-resolution scanning electron microscope S4800, respectively.
Encapsulation
Polymersomes loaded with hydrophobic Nile Red were obtained by incorporating Nile Red in the polymer solution prior to infusion at a ratio of 100 μg Nile Red per 1 mg of PEGPLA. Encapsulation of hydrophilic BSA-Fluorescein was achieved by infusing the polymer solution into a 1 ml aqueous solution of BSA-Fluorescein at a concentration of 1 mg ml−1. Following encapsulation, free dye was removed from samples by 300 kDa membrane dialysis tubes in either MilliQ water or 50 mM NaCl, for spheres or prolates, respectively. Following dialysis, samples were removed from dialysis tubing and transferred to an Amicon 100 kDa microcentrifuge filter unit and centrifuged in Eppendorf Centrifuge 5424 R for 15 min at 5000 RCF. To quantify encapsulated dye, filters were flipped and centrifuged into 200 μl DMSO to dissolve nanoparticles and release encapsulated dye. Fluorescent intensity of the dissolved sample was read for BSA-Fluorescein (486 nm excitation—525 nm emission) and Nile Red (550 nm excitation—640 nm emission) with BioTek Synergy H1M in black clear bottom 96 well assay plates from Corning. Nile Red and BSA-Fluorescein were purchased from Sigma-Aldrich.
In vitro payload release
For release study, polymersomes encapsulating hydrophilic FITC-Dextran were obtained by infusing polymer solution into aqueous solution of FITC-Dextran (0.2 mg ml−1). Following encapsulation, loaded polymersomes were dialyzed (300 kDa membrane dialysis tubes, 15 h) in either MilliQ water or 50 mM NaCl to remove unencapsulated dye. The in vitro payload release from spheres and prolates was conducted in 0.1 M citrate buffer at pH 4.8 for 48 h. Polymersomes were added to mini dialysis device (Slide-A-Lyzer™, 10 K MWCO) and then placed into buffer and incubated at 37 °C with constant shaking. Dialysates were collected and analysed in a microplate reader to determine mass released over the 48 h period, normalized to encapsulation efficiency measured via methods above.
SH-SY5Y culture and administration
SH-SY5Y Neuroblastoma cells were cultured in 250 ml Falcon flasks at 37 degrees Celsius and 5% carbon dioxide. The media used was a 1:1 mixture of Ham’s F12 and EMEM along with 2mM L-Glutamine, 1% Non-Essential Amino Acid, and 15% Fetal Bovine Serum. The cells were given one week between passage along with two media changes in between.
SH-SY5Y fluorescent imaging
SH-SY5Y cells were added to chamber slides with a seeding density of 93 500 cells per well. The slides were allowed to grow for 72 h then washed with PBS. Free-dye solutions were prepared at a concentration of 5.4 μg ml−1 Nile Red and 112.5 μg ml−1 BSA- Fluorescein, based on encapsulation data (table 2). In order to prepare the slides for imaging, free-dye solution, suspension of loaded spherical polymersomes and suspension of loaded prolate polymersomes were administered to wells at 25% of the working volume for four hours. After four hours, the slides were prepared for fluorescent imaging. Vectashield mounting medium with DAPI was added to slides prior to drying overnight. Fluorescent images were taken with Echo Revolve hybrid microscope.
Flow cytometry with cytoflex
Prepared 24-well plate with 50 000 cells per well and grown for 48 h to 70% confluence. The media was removed and washed out with PBS. We administered 450 μl of media and 50 μl of PBS for negative control, 450 μl of media and 50 μl of free-dye solution for positive control, 450 μl of media and 50 μl of spherical nanoparticles loaded with BSA-Fluorescein, and 450 μl of media and 50 μl of prolate nanoparticles loaded with BSA-Fluorescein. After 4 h, the cells were washed three times with cold PBS. They were then trypsinized for one minute with 100 μl of 25% trypsin then removed and replaced with 400 μl of PBS. Each sample was analyzed with Beckman Coulter CytoFlex Flow Cytometer for 10 000 events.
Statistical methods
All statistics were performed using a two-tailed t-test with unequal variance. Statistical significance was defined as p < 0.05.
Supplementary Material
Acknowledgments
We would like to acknowledge Dr James Morris and Christina Wilkinson for assistance with flow cytometry (COBRE Grant P20GM109094). This work was supported in part by the National Science Foundation EPSCoR Program under NSF Award # OIA-1655740. Any Opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect those of the National Science Foundation. This work was also partially supported by Clemson’s Creative Inquiry Program.
Footnotes
Supplementary material for this article is available online
Data availability
The raw/processed data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.
References
- [1].Discher DE and Ahmed F 2006. Polymersomes Annu. Rev. Biomed. Eng. 8 323–41 [DOI] [PubMed] [Google Scholar]
- [2].Onaca O, Enea R, Hughes D W and Meier W 2009. Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery Macromol. Biosci. 9 129–39 [DOI] [PubMed] [Google Scholar]
- [3].Ahmed F, Pakunlu RI, Srinivas G, Brannan A, Bates F, Klein ML, Minko T and Discher D E 2006. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: PH-triggered release through copolymer degradation Mol. Pharm. 3 340–50 [DOI] [PubMed] [Google Scholar]
- [4].Popescu M and Tsitsilianis C 2013. Controlled delivery offunctionalized gold nanoparticles by PH-sensitiveQ5 polymersomes ACS Macro Lett. 2 222–5 [DOI] [PubMed] [Google Scholar]
- [5].Meng F, Zhong Z and Feijen J 2009. Stimuli-responsive polymersomes for programmed drug delivery Biomacromolecules 10 197–209 [DOI] [PubMed] [Google Scholar]
- [6].Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T and Discher DE 2006. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug J. Control. Release 116 150–8 [DOI] [PubMed] [Google Scholar]
- [7].Jain JP and Kumar N 2010. Self assembly of amphiphilic (PEG)(3)-PLA copolymer as polymersomes: preparation, characterization, and their evaluation as drug carrier Biomacromolecules 11 1027–35 [DOI] [PubMed] [Google Scholar]
- [8].Kim J-K, Garripelli VK, Jeong U-H, Park J-S, Repka MA and Jo S 2010. Novel PH-sensitive polyacetal-based block copolymers for controlled drug delivery Int. J. Pharm. 401 79–86 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Kelly JM, Gross AL, Martin DR and Byrne ME 2017. Polyethylene glycol-b-Poly(Lactic Acid) polymersomes as vehicles for enzyme replacement therapy Nanomedicine 12 2591–606 [DOI] [PubMed] [Google Scholar]
- [10].Yu J, Qian C, Zhang Y, Cui Z, Zhu Y, Shen Q, Ligler FS, Buse JB and Gu Z 2017. Hypoxia and H2O2 dual-sensitive vesicles for enhanced glucose-responsive insulin delivery Nano Lett. 17 733–9 [DOI] [PubMed] [Google Scholar]
- [11].Dai L, Cai R, Li M, Luo Z, Yu Y, Chen W, Shen X, Pei Y, Zhao X and Cai K 2017. Dual-targeted cascade-responsive prodrug micelle system for tumor therapy in vivo Chem. Mater. 29 6976–92 [Google Scholar]
- [12].Hu X, Yu J, Qian C, Lu Y, Kahkoska AR, Xie Z, Jing X, Buse JB and Gu Z 2017. H2O2-responsive vesicles integrated with transcutaneous patches for glucose-mediated insulin delivery ACS Nano 11 613–20 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [13].Kulkami P and Mallik S 2018. Drug delivery vehicles from stimuli-responsive block copolymers Novel Nanoscale Hybrid Materials ed B P S Chauhan (New York: Wiley; ) pp 239–61 [Google Scholar]
- [14].Banerjee A, Qi J, Gogoi R, Wong J and Mitragotri S 2016. Role of nanoparticle size, shape and surface chemistry in oral drug delivery J. Control. Release 238 176–85 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].Hao N, Li L, Zhang Q, Huang X, Meng X, Zhang Y, Chen D, Tang F and Li L 2012. The shape effect of pegylated mesoporous silica nanoparticles on cellular uptake pathway in hela cells Microporous Mesoporous Mater. 162 14–23 [Google Scholar]
- [16].Jo DH, Kim JH, Lee TG and Kim JH 2015. Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases Nanomed. Nanotechnol., Biol. Med. 11 1603–11 [DOI] [PubMed] [Google Scholar]
- [17].Larsen JM, Martin DR and Byrne ME 2014. Recent advances in delivery through the blood-brain barrier Curr. Top. Med. Chem. 14 1148–60 [DOI] [PubMed] [Google Scholar]
- [18].Pardridge WM 1997. Drug delivery to the brain J. Cereb. Blood Flow Metab. 17 713–31 [DOI] [PubMed] [Google Scholar]
- [19].Huynh GH, Deen DF and Szoka FC 2006. Barriers to carrier mediated drug and gene delivery to brain tumors J. Control. Release 110 236–59 [DOI] [PubMed] [Google Scholar]
- [20].Pardridge WM 2012. Drug transport across the blood–brain barrier Cereb. Blood Flow Metab. 32 1959–72 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [21].Pardridge WM 2007. Blood-brain barrier delivery Drug Discovery Today 12 54–61 [DOI] [PubMed] [Google Scholar]
- [22].Stenehjem DD, Hartz AMS, Bauer B and Anderson GW 2009. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier Future Med. Chem. 1 1623–41 [DOI] [PubMed] [Google Scholar]
- [23].Nathanson D and Mischel PS 2011. Charting the course across the blood-brain barrier J. Clin. Invest. 121 31–3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [24].Pardridge WM 2012. Drug transport across the blood-brain barrier J. Cereb. Blood Flow Metab. 32 1959–72 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [25].Krol S 2012. Challenges in drug delivery to the brain: nature is against us J. Control. Release 164 145–55 [DOI] [PubMed] [Google Scholar]
- [26].Abbott NJ 2013. Blood-brain barrier structure and function and the challenges for CNS drug delivery J. Inherit. Metab. Dis. 36 437–49 [DOI] [PubMed] [Google Scholar]
- [27].Bell RD and Ehlers MD 2014. Breaching the blood-brain barrier for drug delivery Neuron 81 1–3 [DOI] [PubMed] [Google Scholar]
- [28].Kolhar P, Anselmo AC, Gupta V, Pant K, Prabhakarpandian B, Ruoslahti E and Mitragotri S 2013. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium Proc. Natl Acad. Sci. 110 10753–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [29].Abdelmohsen LKEA, Williams DS, Pille J, Ozel SG, Rikken RSM, Wilson DA and van Hest JCM 2016. Formation of well-defined, functional nanotubes via osmotically induced shape transformation of biodegradable polymersomes J. Am. Chem. Soc. 138 9353–6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [30].Rikken RSM, Engelkamp H, Nolte RJM, Maan JC, Van Hest JCM, Wilson DA and Christianen PCM 2016. Shaping polymersomes into predictable morphologies via out-of-equilibrium self-assembly Nat. Commun. 7 1–7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [31].Salva R, Le Meins JF, Sandre O, Bruîlet A, Schmutz M, Guenoun P and Lecommandoux S 2013. Polymersome shape transformation at the nanoscale ACS Nano 7 9298–311 [DOI] [PubMed] [Google Scholar]
- [32].Men Y, Li W, Janssen G-J A, Rikken RSM and Wilson DA 2018. Stomatocyte in stomatocyte: a new shape of polymersome induced via chemical addition methodology Nano Lett. 18 2081–5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [33].Wauters AC, Pijpers IAB, Mason AF, Williams DS, Tel J, Abdelmohsen LKEA and Van Hest JCM 2019. Development of morphologically discrete PEG–PDLLA nanotubes for precision nanomedicine Biomacromolecules 20 177–83 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [34].Sánchez-Purrà M, Ramos V, Petrenko VA, Torchilin VP and Borrós S 2016. Double-targeted polymersomes and liposomes for multiple barrier crossing Int. J. Pharm. 511 946–56 [DOI] [PubMed] [Google Scholar]
- [35].Trickler WJ et al. 2010. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells Toxicol. Sci. 118 160–70 [DOI] [PubMed] [Google Scholar]
- [36].Ivask A et al. 2017. Uptake and transcytosis of functionalized superparamagnetic iron oxide nanoparticles in an in vitro blood brain barrier model Biomater. Sci. 6 314–23 [DOI] [PubMed] [Google Scholar]
- [37].Abdelmohsen LKEA, Rikken RSM, Christianen PCM, van Hest JCM and Wilson DA 2016. Shape characterization of polymersome morphologies via light scattering techniques Polymer 107 445–9 [Google Scholar]
- [38].Bhattacharjee S 2016. DLS and zeta potential—What they are and what they are not? J. Control. Release 235 337–51 [DOI] [PubMed] [Google Scholar]
- [39].Pistel KF and Kissel T 2000. Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique J. Microencapsul. 17 467–83 [DOI] [PubMed] [Google Scholar]
- [40].Gubernator J, Chwastek G, Korycińska M, Stasiuk M, Grynkiewicz G, Lewrick F, Süss R and Kozubek A 2010. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo J. Control. Release 146 68–75 [DOI] [PubMed] [Google Scholar]
- [41].Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Ceña V, Gallego C and Comella JX 2002. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells J. Neurochem. 75 991–1003 [DOI] [PubMed] [Google Scholar]
- [42].Shipley MM, Mangold CA and Szpara ML 2016. Differentiation of the SH-SY5Y human neuroblastoma cell line JoVE e53193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [43].Lopes FM et al. 2010. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for parkinson disease studies Brain Res. 1337 85–94 [DOI] [PubMed] [Google Scholar]
- [44].Schneider L, Giordano S, Zelickson BR, S Johnson M; A, Benavides G, Ouyang X, Fineberg N, Darley-Usmar VM and Zhang J 2011. Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress Free Radic. Biol. Med. 51 2007–17 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [45].Huang X, Teng X, Chen D, Tang F and He J 2010. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function Biomaterials 31 438–48 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The raw/processed data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.
